Survival Outcome of Combined GnRH Agonist and Tamoxifen Is Comparable to That of Sequential Adriamycin and Cyclophosphamide Chemotherapy Plus Tamoxifen in Premenopausal Patients with Lymph-Node–Negative, Hormone-Responsive, HER2-Negative, T1-T2 Breast Cancer

PURPOSE: The purpose of this study was to compare treatment outcomes between combined gonadotropin-releasing hormone agonist and tamoxifen (GnRHa+T) and sequential adriamycin and cyclophosphamide chemotherapy and tamoxifen (AC->T) in premenopausal patients with hormone-responsive, lymph-node–nega...

Descripción completa

Detalles Bibliográficos
Autores principales: Sohn, Guiyun, Ahn, Sei Hyun, Kim, Hee Jeong, Son, Byung-Ho, Lee, Jong Won, Ko, Beom Seok, Lee, Yura, Lee, Sae Byul, Baek, Seunghee
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Cancer Association 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080815/
https://www.ncbi.nlm.nih.gov/pubmed/27063654
http://dx.doi.org/10.4143/crt.2015.444

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5080815/
https://www.ncbi.nlm.nih.gov/pubmed/27063654
http://dx.doi.org/10.4143/crt.2015.444

Ejemplares similares